Safety of Megadosage Haloprogin

Walter T. Hughes, Sandor Feldman, Harold W. Hermann

Research output: Contribution to journalArticle


A 4-year-old girl with unremitting chronic mucocutaneous candidiasis since 9 months of age was treated topically with haloprogin for a total of 460 days in seven periods of consecutive weeks to months over a 3-year span. During that time, she was given 403 tubes or bottles (30 gm or ml) amounting to about 12,090 gm of a product containing 1% haloprogin. Biochemical, hematologic, and urine examinations were used in monitoring the patient's condition during treatment and showed no evidence of systemic or dermal toxicity.

Original languageEnglish (US)
Pages (from-to)926-928
Number of pages3
JournalArchives of dermatology
Issue number6
StatePublished - Dec 1974


ASJC Scopus subject areas

  • Dermatology

Cite this

Hughes, W. T., Feldman, S., & Hermann, H. W. (1974). Safety of Megadosage Haloprogin. Archives of dermatology, 110(6), 926-928.